Document ID: chunk:federal_register_of_legislation:F2019L01097:reg:9:p2
Version: federal_register_of_legislation:F2019L01097
Segment Type: reg
Provision Reference: reg 9 (pt 2/3)
Character Range: 6751–9635

specified list of aromatic amines is defined in the Schedule 1 – Dictionary.
(6)          inhaling, ingesting or having cutaneous contact with a high concentration of an aromatic amine, through work involving the specified industrial or manufacturing process 2:
(a)          for a cumulative period of at least 3 500 hours before the clinical onset of malignant neoplasm of the bladder; and
(b)          where the first exposure occurred at least ten years before the clinical onset of malignant neoplasm of the bladder;
            Note 1:               Inhaling, ingesting or having cutaneous contact with a high concentration of an aromatic amine does not include exposure due to cigarette smoke or hair dyes.
            Note 2: specified industrial or manufacturing process 2 is defined in the Schedule 1 – Dictionary.
(7)          inhaling, ingesting or having cutaneous contact with tetrachloroethylene for a cumulative period of at least 10 000 hours before the clinical onset of malignant neoplasm of the bladder, where the first exposure occurred at least ten years before the clinical onset of malignant neoplasm of the bladder;
(8)          being exposed to arsenic as specified before the clinical onset of malignant neoplasm of the bladder, where the first exposure to arsenic occurred at least ten years before the clinical onset of malignant neoplasm of the bladder;
Note: being exposed to arsenic as specified is defined in the Schedule 1 – Dictionary.
(9)          working as a painter for a cumulative period of at least 10 000 hours before the clinical onset of malignant neoplasm of the bladder, where that work began at least ten years before the clinical onset of malignant neoplasm of the bladder;
Note: working as a painter is defined in the Schedule 1 – Dictionary.
(10)      having renal stone disease or a bladder stone at least ten years before the clinical onset of malignant neoplasm of the bladder;
(11)      having chronic renal failure at least one year before the clinical onset of malignant neoplasm of the bladder;
Note: chronic renal failure is defined in the Schedule 1 – Dictionary.
(12)      having an infection of the bladder with Schistosoma haematobium at least ten years before the clinical onset of malignant neoplasm of the bladder;
(13)      having an indwelling bladder catheter or other foreign body in the bladder for a continuous period (excepting routine catheter changes) of at least ten years, before the clinical onset of malignant neoplasm of the bladder;
(14)      having neurogenic bladder at least ten years before the clinical onset of malignant neoplasm of the bladder;
Note: neurogenic bladder is defined in the Schedule 1 – Dictionary.
(15)      ingesting aristolochic acid as specified at least four years before the clinical onset of malignant neoplasm of the bladder;
Note: ingesting aristolochic acid as specified is